Showing results (441-450 of 484) with videos related to
Sort By:
Pageof 49
Science Translational Medicine|September 21, 2012
Patient-empowerment interactive technologiesCarol S Bruggers, Roger A Altizer, Robert R Kessler, et al.The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 23, 2024
Donor to recipient age matching in lung transplantation: A European experienceP Pradere, J Le Pavec, S Morisset, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 3, 2005
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatinJ-L Pujol, J-L Breton, R Gervais, et al.Gastrointestinal Endoscopy|July 19, 2019
A comparison of 2 distal attachment mucosal exposure devices: a noninferiority randomized controlled trialDouglas K Rex, Sashidhar V Sagi, William R Kessler, et al.Gastrointestinal Endoscopy|July 13, 2019
Impact of a ring-fitted cap on insertion time and adenoma detection: a randomized controlled trialDouglas K Rex, William R Kessler, Sashidhar V Sagi, et al.Journal of Medical Internet Research|December 31, 2020
Feasibility and Acceptability of a Remotely Delivered, Web-Based Behavioral Intervention for Men With Prostate Cancer: Four-Arm Randomized Controlled Pilot TrialJune M Chan, Erin L Van Blarigan, Crystal S Langlais, et al.Gastrointestinal Endoscopy|May 9, 2015
Narrow-band imaging versus white light for the detection of proximal colon serrated lesions: a randomized, controlled trialDouglas K Rex, Ryan Clodfelter, Farrah Rahmani, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 17, 2016
T Cells Promote Bronchial Epithelial Cell Secretion of Matrix Metalloproteinase-9 via a C-C Chemokine Receptor Type 2 Pathway: Implications for Chronic Lung Allograft DysfunctionM Pain, P-J Royer, J Loy, et al.European Urology Oncology|May 3, 2026
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort EMarinela Augustin, Brigitte Laguerre, Capucine Baldini, et al.The Lancet. Oncology|June 10, 2022
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialRobert J Motzer, Thomas Powles, Mauricio Burotto, et al.Pageof 49